Brought to you by 
Acton takes over US rights to Nasacort HFA from Sanofi US
31 Oct 2011
Executive Summary
Acton Pharmaceuticals Inc. (respiratory therapeutics) has licensed exclusive US rights to Sanofi US’s aerosol nasal allergy treatment Nasacort HFA (triamcinolone acetonide). Financial terms were not disclosed, but Sanofi states that it retains all rights to its already marketed aqueous form Nasacort AQ.
Deal Industry
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Drug Delivery
- Nasal
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Acton takes over US rights to Nasacort HFA from Sanofi US
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice